17/09/2018
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Change of Personnel SHOP APOTHEKE EUROPE N.V. strengthens management team with Stefan Feltens, former CFO of Teva Global Operations, and confirms mid-term annual revenue target of 1 bn EUR.
The designated CEO Stefan Feltens adds: "I am excited to work closely with the managing board to take the growth story of SHOP APOTHEKE EUROPE to the next level." Stefan Feltens has many years of international experience in the pharmaceutical industry and until recently worked as Chief Financial Officer for Teva Global Operations, a division of the world's leading generics company Teva Pharmaceuticals Industries Ltd. with annual sales of USD 20 billion. As a long-term shareholder of Europa Apotheek and current shareholder of SHOP APOTHEKE EUROPE N.V., he is familiar with SHOP APOTHEKE's online pharmacy business. In accordance with Dutch law, Stefan Feltens will be proposed to be appointed as a member of the managing board by the next general shareholders' meeting of SHOP APOTHEKE EUROPE N.V.
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the clear market leader. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 3 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services. SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and will form part of the SDAX on 24 September 2018.
MEDIA CONTACTS. Trade and popular media: Financial media: Investor relations: This release contains statements that relate to future business performance and future financial performance, as well as to events or developments pertaining to SHOP APOTHEKE EUROPE, and that may constitute forward-looking statements. These statements are based on current expectations and assumptions by SHOP APOTHEKE EUROPE's management, a large number of which are beyond the control of SHOP APOTHEKE EUROPE. They are therefore subject to a variety of risks and uncertainties. If these risks and uncertainties materialize, or the underlying expectations do not materialize or the assumptions made prove incorrect, actual events, both in a positive and negative sense, may differ materially from those described or implied in the forward-looking statements. SHOP APOTHEKE EUROPE undertakes no obligation to update these forward-looking statements or to correct them in any other than anticipated development. SHOP APOTHEKE EUROPE also does not intend to do so.
17.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | SHOP APOTHEKE EUROPE N.V. |
Dirk Hartogweg 14 | |
5928 LV Venlo | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | ulrich.wandel@shop-apotheke.com |
Internet: | www.shop-apotheke-europe.com |
ISIN: | NL0012044747, DE000A19Y072 |
WKN: | A2AR94, A19Y07 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |